DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicourete...(rries the risk ofsignificant complicatio...),Health

About Vesicoureteral Reflux (VUR)

Approximately one percent of all children born suffer from VUR, which causes urine to flow backwards from the bladder to the kidneys through one or both of the connecting ureters. In most children, VUR is a birth defect caused by an abnormal connection between the bladder and ureter. Symptoms of VUR include frequent and recurrent urinary tract infections, infrequent or incomplete urination and urgency and frequency. VUR, which tends to run in families, is classified into five grades - I being the mildest and V being the most severe. If a parent has VUR, up to one half of his or her children will also have it, and VUR is 20 percent more likely to occur in the siblings of VUR patients. The average age of diagnosis is one to two years.

About DEFLUX

DEFLUX is a viscous gel consisting of non-animal stabilized hyaluronic acid and dextranomer, a crosslinked polysaccharide that promotes the natural formation of connective tissue. DEFLUX is indicated for the treatment of children with VUR grades II - IV. The most frequent adverse event seen in clinical trials was urinary tract infections. Other adverse events reported -- ureteral dilatation, nausea, vomiting and abdominal pain -- occurred in approximately 1-3% of patients. Rare cases of postoperative dilatation of the upper urinary tract with or without hydronephrosis leading to temporary placement of a ureteric stent have been reported. DEFLUX is contraindicated in patients with non-functioning kidney(s), hutch diverticuli, ureterocele, active voiding dysfunction, or ongoing urinary tract infection. Since 1998, DEFLUX has been used in more than 40,000 children worldwide. Long-term follow up suggests that up to 70 percent of children treated with DEFLUX need no fur
'/>"/>

SOURCE Q-Med Copyright©2007 PR Newswire.

2 GOOD